



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/723,923	11/25/2003	Qing Wang	ROGO 217 (10309708)	9786
24972	7590	12/23/2004	EXAMINER	
FULBRIGHT & JAWORSKI, LLP			DO, PENSEE T	
666 FIFTH AVE			ART UNIT	PAPER NUMBER
NEW YORK, NY 10103-3198			1641	

DATE MAILED: 12/23/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/723,923

Applicant(s)

WANG ET AL.

Examiner

Pensee T. Do

Art Unit

1641

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 23 February 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 7 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7, "HCl" is indefinite because it is an abbreviation. Please spell out the abbreviation for abbreviation may have more than one meaning.

In claim 4, the use of the trademark Tacromilus (FK-506) has been noted in this application. It should be capitalized wherever it appears and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 7-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Bieniarz et al.(US 5,063,109).

Bieniarz teaches a method of attaching a ligand to a solid phase comprising contacting an amine microparticles with 2-iminothiolane HCl (a molecule which reacts with amine); reacting a conjugate comprising maleimide derivatized antibodies (linker-ligand) with said iminothiolane HCL-solid phase to attach the ligand to the microparticles. (see examples 7 & 16, especially col. 13, lines 33-40). Regarding the limitation of the molecule contains a protected or unprotected sulfhydryl group, since Bieniarz teaches the same molecule as of the invention, such molecule must contain a protected or unprotected sulfhydryl group and must also react with the amine group in an acylation reaction. Bieniarz's solid phase with a ligand attached thereto satisfies the requirement of claim 9.

Claims 1, 5, 8, 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Pope et al. (US 5,399,501).

Pope teaches a method for attaching a ligand to a solid phase comprising: contacting an amine group on the surface of a solid phase with a molecule comprising a thiol introducing agent such as thiolanes, succinimidyl thioacetates such as N-succinimidyl-S-acetylthioacetate, and disulfide compounds which are subsequently reduced to a thiol. The specific binding member is activated by a maleimido-NHS active ester heterobifunctional reagent to incorporate a thiol-reactive group on the protein. The derivatized specific binding member is then added to the thiolated solid phase and reacted to produce a covalent linkage. Regarding claim 8, since Pope teaches the same molecule, i.e. thiolanes or succinimidyl thioacetates, such molecule would react with the amine group on the solid phase via a acylation reaction. Pope's solid phase with a

Art Unit: 1641

ligand attached thereto satisfies the requirement of claim 9. The specific binding pair member includes that binds with the analyte which are protein, peptide, an amino acid, a drug include those administered for therapeutic purposes, a bacterium, a virus, and metabolites. The solid phase include polymeric or glass beads, microparticles, tubes, sheets, plates, etc. (see col. 6, lines 8-52; col. 7, lines 27-60; col. 8, lines 16-68; col. 9, line 49-col. 10, line 15).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over Bieniarz in view of Hansen et al. (US 6,663,861).

Bieniarz has been discussed above.

However, Bieniarz fails to teach a linker as p-maleimidophenyl isocyanate.

Hansen teaches various methods of covalent coupling such as coupling a molecule with sulfhydryl groups to hydroxyl groups by using a N-(p-maleimidophenyl) isocyanate. (see col. 5, lines 15-25).

It would have been obvious to one of ordinary skills in the art to use N-(p-maleimidophenyl) isocyanate as a linker as suggested by Hansen to link the ligand which contains a hydroxyl group to 2-iminothiolane-HCl which contains a sulfhydryl group as taught in the method of Bieniarz since Bieniarz teaches using a maleimide for

Art Unit: 1641

linking the ligand which contains a hydroxyl group and a sulfhydryl group. N-(p-maleimidophenyl) isocyanate is known as a heterobifunctional crosslinker which links a ligand to a solid surface.

Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Bieniarz (US 5,063,109) in view of Siiman et al. (US 5,639,620).

Bieniarz has been discussed above.

However, Bieniarz fails to teach magnetic particles being the solid phase.

Siiman teaches magnetic particles coated with aminodextran or gelatin which contains an amine pendent group. Crosslink the ligand/protein/antibody with the magnetic particles by using the bifunctional crosslinking agent such as p-iminothiolane hydrochloride. The coupling of the biological substance to the particle involves activation of the free amino groups of the gelatin-coated particles with a water soluble heterobifunctional reagent such as 2-iminothiolane hydrochloride (IT), sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester, N-succinimidyl-3-(2-pyridyldithio)propionate, succinimidyl-4-(p-maleimidophenyl)butyrate, N-succinimidyl-(4-iodoacetyl)aminobenzoate, the reagents listed above as substitutes for glutaraldehyde and the like. The 2-iminothiolane hydrochloride and the maleimidyl/succinimidyl reagents are preferred. (see col. 7, lines 60-65; col. 10, lines 15-25, 53-60)

It would have been obvious to one of ordinary skills in the art to use magnetic particles as a solid phase as taught by Siiman in the method of Bieniarz since both

references teach a method of conjugating a ligand to a solid surface via a bifunctional crosslinking agent and because ligand bound magnetic particles, in an immunoassay, can be separated by magnetic force rather than centrifugation which is time consuming.

Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pope et al. (US 5,399,501) in view of Armstrong (US 5,964,996).

Pope has been discussed above.

However, Pope fails to teach the ligand is an antibiotic.

Armstrong teaches macrocyclic antibiotic chemically bonded to a solid support such as silica gel, agarose, dextran, cellulose, branch amylose (see col. 6, lines 58-67; col. 7, lines 5-10). via linkages such as amine, amide, thiol groups (see col. 7, lines 27-30).

It would have been obvious to one of ordinary skills in the art to attach antibiotic as taught by Armstrong to solid phase according to the method of Pope through routine experimentation since these antibiotics also contain a carboxyl or thioether groups thereby enabling the reaction with a coupling agent or thiol introducing agent.

Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pope et al. (US 5,399,501) in view of Armstrong (US 5,964,996) further in view of Molna-Kimber et al. (US Patent Application Publication 2002/0151088A1).

Pope and Armstrong have been discussed above.

Both Pope and Armstrong fail to teach antibiotic such as Rapamycin.

Molna-Kimber teaches rapamycin is a macrocyclic antibiotic. (see page 1, 1st col. 2nd paragraph).

It would have been obvious to one of ordinary skills to use Rapamycin as taught by Molna-Kimber in the combination method of Pope and Armstrong since Rapamycin is a macrocyclic antibiotic and Pope in combination with Armstrong suggested that macrocyclic antibiotics can be coupled to a solid phase for detecting specific antibodies against antibiotics such as Rapamycin because Rapamycin have immunosuppressant activity as well as antibiotic and other pharmacological activities and are useful in treating graft and transplant rejections, diseases of inflammation and autoimmune diseases such as rheumatoid arthritis, diabetes, and multiple sclerosis.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Pensee T. Do whose telephone number is 571-272-0819. The examiner can normally be reached on Monday-Friday, 7:00-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/723,923
Art Unit: 1641

Page 8

Pensee T. Do
Patent Examiner
December 8, 2004

Christopher L. Chin

CHRISTOPHER L. CHIN
PRIMARY EXAMINER
GROUP 1800-1641
12/13/04